EAD (TTM)

EAD/share (TTM)

EAD (Quarter)

EAD/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/EAD

Based in Westbury, NY, ACRES Commercial Realty Corp is a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and other commercial real estate-related debt investments. The Company is externally managed by ACRES Capital, LLC, a subsidiary of ACRES Capital Corp., a private commercial real estate lender exclusively dedicated to nationwide middle market CRE lending with a focus on multifamily, student housing, hospitality, office, industrial and other asset types in top US markets.

ACRES Commercial Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

Period: 2022 Q4

Years since IPO: 15/15,
EAD Growth: 1/15,
EAD/share Growth: 1/20,
Dividend Growth: 5/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q1

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q2

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q3

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q4

Years since IPO: 15/15,
EAD Growth: 6/15,
EAD/share Growth: 11/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q1

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q2

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q3

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q4

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q1

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q2

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q3

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's EAD

EAD Growth

Assessment of recent increases in EAD per share, indicating profitability

EAD/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

UNIONDALE, N.Y. , Oct. 29, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE:ACR) (the "Company") announced today that its board of directors (the "Board") authorized and approved the continued use of its existing share repurchase program to repurchase an additional $7.5 million of the outstanding shares of both its common and preferred stock.

ACRES Commercial Realty Corp. Reauthorizes an Additional $7.5 Million Share Repurchase Program

UNIONDALE, N.Y. , Oct. 29, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company"), a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and equity investments in commercial real estate property through direct ownership and joint ventures, today reported results for the quarter ended September 30, 2025.

ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR THIRD QUARTER 2025

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-breaking data from the robust, global 424-patient Phase 2b trial of rosnilimab, a selective and potent pathogenic T cell depleter, in rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Convergence 2025 in Chicago. New study results showed that positive Week 12 data across multiple higher-order response measures continue to deepen into Week 28 regardless of prior treatment. These results were then durable for at least three months off drug. Additionally, rosnilimab was well-tolerated with no treatment-related serious adverse events and no malignancies in rosnilimab-treated patients through end-of-trial follow-up (Week 38).

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois.

Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Treatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally acting, non-opioid analgesic and therapeutic option for adults with fibromyalgia

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis registrational trial being initiated this quarter with a planned cohort of 14 DM/ASyS patients and a 16-week primary endpoint – moderate or major TIS while off immunomodulators and on no or low-dose steroids – consistent with FDA alignment on key trial parameters – – All systemic sclerosis patients with sufficient follow-up demonstrated ongoing, transformative clinical responses off all immunomodulators and steroids – – Seven of 8 lupus patients with sufficient follow-up achieved DORIS or renal response; RESET-SLE™ trial expanding to include a no preconditioning cohort with initial clinical data expected in 2026 – – 76 patients enrolled at 77 clinical trial sites globally as of October 24, 2025 – PHILADELPHIA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced positive clinical data and development updates across the RESET-Myositis™, RESET-SSc™ and RESET-SLE trials evaluating rese-cel (resecabtagene autoleucel, formerly known as CABA-201). These data are being presented in multiple oral and poster presentations at the ongoing American College of Rheumatology (ACR) Convergence 2025, which is being held at the McCormick Place Convention Center in Chicago, Illinois, from October 24-29, 2025.

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, will present new preclinical data for CLN-978, its novel investigational CD19xCD3 bispecific T cell engager.

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA)

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the ACR Convergence Congress.

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model  Data support the potential of MRT-6160 to address multiple rheumatic autoimmune and inflammatory diseases, including Sjögren's disease, systemic lupus erythematosus, and rheumatoid arthritis Poster presentation on October 26th at 10:30 am CDT BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of MRT-6160, a rationally designed molecular glue degrader (MGD) that selectively degrades VAV1, to treat multiple autoimmune and inflammatory diseases, at ACR Convergence 2025, held October 24-29 in Chicago, IL. “In a preclinical autoimmune disease model characterized by chronic inflammation, autoantibody production, and multi-organ involvement, administration of MRT-6160 resulted in broad activity across an array of disease markers, including attenuated autoantibody levels and reduced skin and kidney pathology,” said Sharon Townson, Ph.D.

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

Mechelen, Belgium ; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24-29, 2025.

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting.

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

CHATHAM, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets), which was investigated as TNX-102 SL, will be presented by Dr. Gregory Sullivan, M.D.

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Advertisers gain access to ACR audiences through Yahoo DSP across the U.S., U.K. and Germany Advertisers gain access to ACR audiences through Yahoo DSP across the U.S., U.K. and Germany

Nexxen's ACR Audience Segments Licensed by Yahoo DSP for Activation

UNIONDALE, N.Y. , Oct. 15, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that it will release its results for the third quarter 2025, on Wednesday, October 29, 2025, after the market closes.

ACRES Commercial Realty Corp. to Report Results for Third Quarter 2025

Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-point ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) reduction vs 19.3% on placebo at 24 weeks Sustained efficacy and favorable safety profile through 48 weeks support potential best-in-disease profile in primary Sjögren's disease (pSD) Company evaluating timing of global Phase 3 clinical study in primary Sjögren's disease Vor Bio to host a conference call on Tuesday, October 28, 2025 at 4:30PM ET BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), reported positive 48-week results from its Phase 3 study conducted in China evaluating telitacicept in primary Sjögren's disease. The study met its primary endpoint of change from baseline in ESSDAI at week 24, as well as all secondary endpoints, with the telitacicept 160mg dose achieving highly significant p values (p

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in rheumatoid arthritis (RA), was accepted for a late-breaking oral presentation at American College of Rheumatology (ACR) Convergence 2025 in Chicago, IL, Oct. 24 – 29, 2025.

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren's disease, a study sponsored by Vor's collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chicago, Illinois.

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025

Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

Autolus announces the publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025.

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

UNIONDALE, N.Y. , Sept. 15, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.

ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock

UNIONDALE, N.Y. , OCT. 29, 2025 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP. (NYSE:ACR) (THE "COMPANY") ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS (THE "BOARD") AUTHORIZED AND APPROVED THE CONTINUED USE OF ITS EXISTING SHARE REPURCHASE PROGRAM TO REPURCHASE AN ADDITIONAL $7.5 MILLION OF THE OUTSTANDING SHARES OF BOTH ITS COMMON AND PREFERRED STOCK.

ACRES COMMERCIAL REALTY CORP. REAUTHORIZES AN ADDITIONAL $7.5 MILLION SHARE REPURCHASE PROGRAM

UNIONDALE, N.Y. , OCT. 29, 2025 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP. (NYSE: ACR) ("ACR" OR THE "COMPANY"),A REAL ESTATE INVESTMENT TRUST THAT IS PRIMARILY FOCUSED ON ORIGINATING, HOLDING AND MANAGING COMMERCIAL REAL ESTATE MORTGAGE LOANS AND EQUITY INVESTMENTS IN COMMERCIAL REAL ESTATE PROPERTY THROUGH DIRECT OWNERSHIP AND JOINT VENTURES, TODAY REPORTED RESULTS FOR THE QUARTER ENDED SEPTEMBER30, 2025.

SAN DIEGO, OCT. 29, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED LATE-BREAKING DATA FROM THE ROBUST, GLOBAL 424-PATIENT PHASE 2B TRIAL OF ROSNILIMAB, A SELECTIVE AND POTENT PATHOGENIC T CELL DEPLETER, IN RHEUMATOID ARTHRITIS (RA) AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025 IN CHICAGO. NEW STUDY RESULTS SHOWED THAT POSITIVE WEEK 12 DATA ACROSS MULTIPLE HIGHER-ORDER RESPONSE MEASURES CONTINUE TO DEEPEN INTO WEEK 28 REGARDLESS OF PRIOR TREATMENT. THESE RESULTS WERE THEN DURABLE FOR AT LEAST THREE MONTHS OFF DRUG. ADDITIONALLY, ROSNILIMAB WAS WELL-TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AND NO MALIGNANCIES IN ROSNILIMAB-TREATED PATIENTS THROUGH END-OF-TRIAL FOLLOW-UP (WEEK 38).

ANAPTYS ANNOUNCES NEW POSITIVE PHASE 2B TRIAL RESULTS FOR ROSNILIMAB IN RHEUMATOID ARTHRITIS AT ACR LATE-BREAKING ORAL PRESENTATION

NESS-ZIONA, ISRAEL, OCT. 28, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT IT WILL PRESENT A LATE-BREAKING POSTER ABSTRACT AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025, TAKING PLACE OCTOBER 2429 AT MCCORMICK PLACE CONVENTION CENTER IN CHICAGO, ILLINOIS.

ENLIVEX THERAPEUTICS TO PRESENT PHASE IIA 3-MONTH DATA OF ALLOCETRA IN PATIENTS WITH MODERATE-TO-SEVERE KNEE OSTEOARTHRITIS AT THE ACR CONVERGENCE 2025

 ALL MYOSITIS PATIENTS IN THE PHASE 1/2 DM/ASYS COHORT WITH SUFFICIENT FOLLOW-UP WHO MET KEY REGISTRATIONAL INCLUSION CRITERIA EXCEEDED THE REGISTRATIONAL PRIMARY ENDPOINT, DEMONSTRATING MAJOR TIS RESPONSES WITH NO IMMUNOMODULATORS   MYOSITIS REGISTRATIONAL TRIAL BEING INITIATED THIS QUARTER WITH A PLANNED COHORT OF 14 DM/ASYS PATIENTS AND A 16-WEEK PRIMARY ENDPOINT  MODERATE OR MAJOR TIS WHILE OFF IMMUNOMODULATORS AND ON NO OR LOW-DOSE STEROIDS  CONSISTENT WITH FDA ALIGNMENT ON KEY TRIAL PARAMETERS   ALL SYSTEMIC SCLEROSIS PATIENTS WITH SUFFICIENT FOLLOW-UP DEMONSTRATED ONGOING, TRANSFORMATIVE CLINICAL RESPONSES OFF ALL IMMUNOMODULATORS AND STEROIDS   SEVEN OF 8 LUPUS PATIENTS WITH SUFFICIENT FOLLOW-UP ACHIEVED DORIS OR RENAL RESPONSE; RESET-SLE TRIAL EXPANDING TO INCLUDE A NO PRECONDITIONING COHORT WITH INITIAL CLINICAL DATA EXPECTED IN 2026   76 PATIENTS ENROLLED AT 77 CLINICAL TRIAL SITES GLOBALLY AS OF OCTOBER 24, 2025  PHILADELPHIA, OCT. 27, 2025 (GLOBE NEWSWIRE) -- CABALETTA BIO, INC. (NASDAQ: CABA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND LAUNCHING THE FIRST CURATIVE TARGETED CELL THERAPIES DESIGNED SPECIFICALLY FOR PATIENTS WITH AUTOIMMUNE DISEASES, TODAY ANNOUNCED POSITIVE CLINICAL DATA AND DEVELOPMENT UPDATES ACROSS THE RESET-MYOSITIS, RESET-SSC AND RESET-SLE TRIALS EVALUATING RESE-CEL (RESECABTAGENE AUTOLEUCEL, FORMERLY KNOWN AS CABA-201). THESE DATA ARE BEING PRESENTED IN MULTIPLE ORAL AND POSTER PRESENTATIONS AT THE ONGOING AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025, WHICH IS BEING HELD AT THE MCCORMICK PLACE CONVENTION CENTER IN CHICAGO, ILLINOIS, FROM OCTOBER 24-29, 2025.

CABALETTA BIO PRESENTS POSITIVE CLINICAL DATA AND DEVELOPMENT UPDATES FOR RESE-CEL AT ACR CONVERGENCE 2025

TONMYA DEMONSTRATED SIGNIFICANT REDUCTION IN FIBROMYALGIA PAIN COMPARED WITH PLACEBO IN THE PHASE 3 RESILIENT STUDY TREATMENT WAS WELL TOLERATED WITH MINIMAL EFFECTS ON WEIGHT OR BLOOD PRESSURE AND DISCONTINUATION RATE OF 19% VS. PLACEBO OF 20.8% DATA SUPPORT THE POTENTIAL OF TONMYA AS A WELL-TOLERATED, CENTRALLY ACTING, NON-OPIOID ANALGESIC AND THERAPEUTIC OPTION FOR ADULTS WITH FIBROMYALGIA

TONIX PHARMACEUTICALS PRESENTED DATA ON TONMYA (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) AT THE 2025 AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE

AS OF A SEPTEMBER 25, 2025 DATA CUT-OFF-DATE, 10 PATIENTS WITH TREATMENT-REFRACTORY, MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WERE TREATED WITH A SINGLE DOSE OF FT819 WITH LESS-INTENSIVE OR NO CONDITIONING CHEMOTHERAPY

FATE THERAPEUTICS PRESENTS NEW CLINICAL DATA AT ACR CONVERGENCE 2025 DEMONSTRATING IMMUNE REMODELING AND DURABLE RESPONSES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH FT819 OFF-THE-SHELF CAR T-CELL THERAPY

CLN-978 LED TO RAPID AND DEEP B CELL DEPLETION IN VITRO AND IN VIVO IN MULTIPLE AUTOIMMUNE DISEASES CAMBRIDGE, MASS., OCT. 25, 2025 (GLOBE NEWSWIRE) -- CULLINAN THERAPEUTICS, INC. (NASDAQ: CGEM), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ACCELERATING POTENTIAL FIRST- OR BEST-IN-CLASS, HIGH-IMPACT THERAPIES IN AUTOIMMUNE DISEASES AND CANCER, WILL PRESENT NEW PRECLINICAL DATA FOR CLN-978, ITS NOVEL INVESTIGATIONAL CD19XCD3 BISPECIFIC T CELL ENGAGER.

CULLINAN THERAPEUTICS SHARES ADDITIONAL PRECLINICAL B CELL DEPLETION DATA FOR CLN-978, SUPPORTING CLINICAL DEVELOPMENT ACROSS MULTIPLE AUTOIMMUNE DISEASES, AT ACR CONVERGENCE 2025

KYV-101 RESULTED IN A PROFOUND REDUCTION IN DISEASE-ASSOCIATED AUTOANTIBODIES AND IMPACT ON DISEASE ACTIVITY IN PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS (RA)

KYVERNA THERAPEUTICS HIGHLIGHTS POTENTIAL OF KYV-101 IN RHEUMATOID ARTHRITIS WITH PHASE 1 DATA FROM INVESTIGATOR-INITIATED TRIAL PRESENTED AT ACR CONVERGENCE 2025

WALTHAM, MASS., OCT. 24, 2025 (GLOBE NEWSWIRE) -- SPYRE THERAPEUTICS, INC. (NASDAQ: SYRE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING LONG-ACTING ANTIBODIES AND ANTIBODY COMBINATIONS TO REDEFINE THE STANDARD OF CARE FOR INFLAMMATORY BOWEL DISEASE (IBD) AND RHEUMATIC DISEASES, TODAY ANNOUNCED SCIENTIFIC PRESENTATIONS AT THE ACR CONVERGENCE CONGRESS.

SPYRE THERAPEUTICS ANNOUNCES POSTER PRESENTATIONS AT AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025

MRT-6160 INHIBITED DISEASE PATHOLOGY, INCLUDING PROTEINURIA, LYMPHADENOPATHY, SKIN LESION FORMATION, AUTOANTIBODY PRODUCTION, AND ORGANOMEGALY, IN A SPONTANEOUS AUTOIMMUNE DISEASE MOUSE MODEL DATA SUPPORT THE POTENTIAL OF MRT-6160 TO ADDRESS MULTIPLE RHEUMATIC AUTOIMMUNE AND INFLAMMATORY DISEASES, INCLUDING SJGREN'S DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS, AND RHEUMATOID ARTHRITIS POSTER PRESENTATION ON OCTOBER 26TH AT 10:30 AM CDT BOSTON, OCT. 24, 2025 (GLOBE NEWSWIRE) -- MONTE ROSA THERAPEUTICS, INC.(NASDAQ: GLUE), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MOLECULAR GLUE DEGRADER (MGD)-BASED MEDICINES, TODAY ANNOUNCED THE COMPANY WILL PRESENT PRECLINICAL DATA ON THE POTENTIAL OF MRT-6160, A RATIONALLY DESIGNED MOLECULAR GLUE DEGRADER (MGD) THAT SELECTIVELY DEGRADES VAV1, TO TREAT MULTIPLE AUTOIMMUNE AND INFLAMMATORY DISEASES, AT ACR CONVERGENCE 2025, HELD OCTOBER 24-29 IN CHICAGO, IL. IN A PRECLINICAL AUTOIMMUNE DISEASE MODEL CHARACTERIZED BY CHRONIC INFLAMMATION, AUTOANTIBODY PRODUCTION, AND MULTI-ORGAN INVOLVEMENT, ADMINISTRATION OF MRT-6160 RESULTED IN BROAD ACTIVITY ACROSS AN ARRAY OF DISEASE MARKERS, INCLUDING ATTENUATED AUTOANTIBODY LEVELS AND REDUCED SKIN AND KIDNEY PATHOLOGY, SAID SHARON TOWNSON, PH.D.

MONTE ROSA THERAPEUTICS PRESENTS PRECLINICAL DATA AT ACR CONVERGENCE 2025 ON THE POTENTIAL OF MRT-6160, A VAV1-DIRECTED MOLECULAR GLUE DEGRADER, TO TREAT IMMUNE-MEDIATED DISEASES

MECHELEN, BELGIUM ; OCTOBER 23, 2025, 22:01 CET; GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) TODAY ANNOUNCED THAT IT WILL PRESENT NEW IN VITRO PHARMACOLOGICAL DATA FROM ITS SELECTIVE TYK2 INHIBITOR, GLPG3667, CURRENTLY IN TWO PHASE 3-ENABLING STUDIES IN DERMATOMYOSITIS (DM) AND SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025, TAKING PLACE IN CHICAGO, IL, OCTOBER 24-29, 2025.

GALAPAGOS TO PRESENT IN VITRO DATA AT ACR CONVERGENCE 2025 SUGGESTING DIFFERENTIATION OF GLPG3667 FROM OTHER TYK2 INHIBITORS

AP3 GENERATIVE AI KAISR MODEL GLOBALLY ASSESSES DRUG EFFECTS ON THE ENTIRE INTRACELLULAR PROTEIN SIGNALING NETWORK FOR OPTIMAL DRUG DESIGN AND PRECISION MEDICINE DEVELOPMENT

ACRIVON THERAPEUTICS HIGHLIGHTS ITS POWERFUL GENERATIVE PHOSPHOPROTEOMICS AP3 PLATFORM WITH COMPELLING PRECLINICAL DATA FOR ACR-2316 WITH THREE PRESENTATIONS AT THE UPCOMING AACR-NCI-EORTC INTERNATIONAL CONFERENCE

SOUTH SAN FRANCISCO, CALIF., OCT. 22, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASE, TODAY ANNOUNCED IT WILL BE PRESENTING A POSTER THIS SUNDAY IN CHICAGO AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025 MEETING.

NKARTA ANNOUNCES POSTER PRESENTATION AT UPCOMING AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE MEETING

CHATHAM, N.J., OCT. 21, 2025 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (TONIX OR THE COMPANY), A FULLY-INTEGRATED, COMMERCIAL BIOTECHNOLOGY COMPANY, ANNOUNCED TODAY THAT A POSTER ON TONMYA(CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS), WHICH WAS INVESTIGATED AS TNX-102 SL, WILL BE PRESENTED BY DR. GREGORY SULLIVAN, M.D.

TONIX PHARMACEUTICALS TO PRESENT POSTER ON TONMYAAT THE 2025 AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE

ADVERTISERS GAIN ACCESS TO ACR AUDIENCES THROUGH YAHOO DSP ACROSS THE U.S., U.K. AND GERMANY ADVERTISERS GAIN ACCESS TO ACR AUDIENCES THROUGH YAHOO DSP ACROSS THE U.S., U.K. AND GERMANY

NEXXEN'S ACR AUDIENCE SEGMENTS LICENSED BY YAHOO DSP FOR ACTIVATION

UNIONDALE, N.Y. , OCT. 15, 2025 /PRNEWSWIRE/ --ACRES COMMERCIAL REALTY CORP. (NYSE: ACR) (THE "COMPANY") ANNOUNCED TODAY THAT IT WILL RELEASE ITS RESULTS FOR THE THIRD QUARTER 2025, ON WEDNESDAY, OCTOBER 29, 2025, AFTER THE MARKET CLOSES.

ACRES COMMERCIAL REALTY CORP. TO REPORT RESULTS FOR THIRD QUARTER 2025

TELITACICEPT MET PRIMARY AND ALL SECONDARY ENDPOINTS, DEMONSTRATING CLINICALLY MEANINGFUL IMPROVEMENTS IN DISEASE ACTIVITY VERSUS PLACEBO ~71.8% OF PATIENTS RECEIVING TELITACICEPT 160MG ACHIEVED 3-POINT ESSDAI (EULAR SJGREN'S SYNDROME DISEASE ACTIVITY INDEX) REDUCTION VS 19.3% ON PLACEBO AT 24 WEEKS SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE THROUGH 48 WEEKS SUPPORT POTENTIAL BEST-IN-DISEASE PROFILE IN PRIMARY SJGREN'S DISEASE (PSD) COMPANY EVALUATING TIMING OF GLOBAL PHASE 3 CLINICAL STUDY IN PRIMARY SJGREN'S DISEASE VOR BIO TO HOST A CONFERENCE CALL ON TUESDAY, OCTOBER 28, 2025 AT 4:30PM ET BOSTON, OCT. 14, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT ITS COLLABORATOR, REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), REPORTED POSITIVE 48-WEEK RESULTS FROM ITS PHASE 3 STUDY CONDUCTED IN CHINA EVALUATING TELITACICEPT IN PRIMARY SJGREN'S DISEASE. THE STUDY MET ITS PRIMARY ENDPOINT OF CHANGE FROM BASELINE IN ESSDAI AT WEEK 24, AS WELL AS ALL SECONDARY ENDPOINTS, WITH THE TELITACICEPT 160MG DOSE ACHIEVING HIGHLY SIGNIFICANT P VALUES (P

TELITACICEPT DEMONSTRATES CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT IMPACT ON ESSDAI COMPARED TO PLACEBO IN LATE-BREAKING CHINA PHASE 3 RESULTS IN PRIMARY SJGREN'S DISEASE AT ACR 2025

SAN DIEGO, OCT. 13, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED THAT COMPLETE DATA FROM THE PHASE 2B TRIAL OF ROSNILIMAB, A PATHOGENIC T CELL DEPLETER, IN RHEUMATOID ARTHRITIS (RA), WAS ACCEPTED FOR A LATE-BREAKING ORAL PRESENTATION AT AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025 IN CHICAGO, IL, OCT. 24  29, 2025.

ANAPTYS ANNOUNCES LATE-BREAKING ORAL PRESENTATION OF COMPLETE PHASE 2B DATA FOR ROSNILIMAB IN RHEUMATOID ARTHRITIS AT UPCOMING ACR CONVERGENCE 2025

BOSTON, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- VOR BIO (NASDAQ: VOR), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY TRANSFORMING THE TREATMENT OF AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT CLINICAL DATA FROM THE PHASE 3 STUDY IN CHINA EVALUATING TELITACICEPT IN ADULTS WITH PRIMARY SJGREN'S DISEASE, A STUDY SPONSORED BY VOR'S COLLABORATOR REMEGEN CO., LTD (HKEX: 9995, SHA: 688331), WILL BE PRESENTED AS A LATE-BREAKING POSTER PRESENTATION AT ACR CONVERGENCE 2025, BEING HELD OCTOBER 24-29, 2025, AT MCCORMICK PLACE IN CHICAGO, ILLINOIS.

VOR BIO ANNOUNCES LATE-BREAKING POSTER PRESENTATION OF PHASE 3 PRIMARY SJGREN'S DISEASE CLINICAL STUDY AT ACR CONVERGENCE 2025

HIGHLIGHTS DISCOVERY OF NOVEL TARGETS IN T CELL-DRIVEN AUTOIMMUNE DISORDERS; INITIAL FINDINGS TO BE PRESENTED AT THE ACR CONVERGENCE 2025 HIGHLIGHTS DISCOVERY OF NOVEL TARGETS IN T CELL-DRIVEN AUTOIMMUNE DISORDERS; INITIAL FINDINGS TO BE PRESENTED AT THE ACR CONVERGENCE 2025

TSCAN THERAPEUTICS ANNOUNCES UPCOMING ORAL AND POSTER PRESENTATIONS AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2025

AUTOLUS ANNOUNCES THE PUBLICATION OF AN ABSTRACT SUBMITTED TO THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025, TO BE HELD OCTOBER 24-29, 2025.

AUTOLUS THERAPEUTICS TO PRESENT CLINICAL DATA UPDATE AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025

UNIONDALE, N.Y. , SEPT. 15, 2025 /PRNEWSWIRE/ --ACRES COMMERCIAL REALTY CORP.(NYSE: ACR) (THE "COMPANY") ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS DECLARED CASH DIVIDENDS ON ITS PREFERRED STOCK.

ACRES Commercial Realty

ACR

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ACR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ACR